Church & Dwight R&D decreased by 12.7% to $31.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.7%, from $32.80M to $31.60M.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.40M | $27.70M | $24.50M | $27.20M | $29.20M | $26.70M | $30.20M | $30.30M | $30.10M | $33.00M | $36.00M | $32.80M | $35.80M | $36.20M | $31.60M |
| QoQ Change | — | +9.1% | -11.6% | +11.0% | +7.4% | -8.6% | +13.1% | +0.3% | -0.7% | +9.6% | +9.1% | -8.9% | +9.1% | +1.1% | -12.7% |
| YoY Change | — | — | — | +7.1% | +5.4% | +9.0% | +11.0% | +3.8% | +12.7% | +9.3% | +18.8% | +9.0% | +8.5% | +0.6% | -3.7% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Consumer Domestic | $29.20M | $31.80M | $32.30M | $35.80M | $27.80M |
| Consumer International | $3.00M | $3.20M | $3.20M | $4.10M | $3.00M |
| Specialty Products Division | $600.00K | $800.00K | $700.00K | $900.00K | $800.00K |
| Consolidating Reclassification | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total | $32.80M | $35.80M | $36.20M | — | $31.60M |